Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Cyclophosphamide 19romidepsin 15fludarabine phosphate 13Whole-Body Irradiation 13Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Doxorubicin 11Vincristine 10Prednisone 10Cyclosporine 1010-propargyl-10-deazaaminopterin 10Gemcitabine 8Etoposide 8Alemtuzumab 8Bortezomib 6Dexamethasone 5Busulfan 5Brentuximab Vedotin 5mogamulizumab 4denileukin diftitox 4darinaparsin 4Vitamin B 12 4Nivolumab 4Lenalidomide 4Folic Acid 4Carboplatin 4carfilzomib 3belinostat 3Tacrolimus 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Peripheral × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡